Diabetes

Insulin glargine is a recombinant human insulin analog that is a long-acting, parenteral blood-glucose-lowering agent. Insulin glargine has low aqueous solubility at neutral pH. At pH 4 insulin glargine is completely soluble. After injection into the subcutaneous tissue, the acidic solution is neutralized, leading to formation of micro precipitates from which small amounts of insulin glargine are slowly released, resulting in a relatively constant concentration/time profile over 24 hours with no pronounced peak. This profile allows once-daily dosing as a basal insulin.

LANTUS is produced by recombinant DNA technology utilizing a non-pathogenic laboratory strain of Escherichia coli as the production organism. Insulin glargine differs from human insulin in that the amino acid asparagine at position A21 is replaced by glycine and two arginines are added to the C-terminus of the B-chain. Chemically, insulin glargine is 21A-Gly-30Ba-L-Arg-30Bb-L-Arg-human insulin and has the empirical formula C267H404N72O78S6 and a molecular weight of 6063 Da.

Insulin Glargine from LOKA

Is an injection of sterile solution of insulin glargine for subcutaneous use.

Is manufactured as Bulk Glargine API

Is manufactured at a capacity of 10 Kilograms ( Equivalent to 1 million Cartridges/PFS/Vials)

Insulin is produced by recombinant DNA technology utilizing a non-pathogenic laboratory strain of Escherichia coli as the production organism. Insulin injection is a sterile solution of insulin for subcutaneous use. Insulin has a molecular weight of 5800 Da.

Regular Insulin from LOKA

Is manufactures as Bulk Insulin API

Is manufactured at a capacity of 10 Kilograms ( Equivalent to 1 million Cartridges/PFS/Vials)text goes here

hEGF is Human Epidermal Growth Factor produced using recombinant technology. It is a new generation therapy for diabetic foot ulcers, pressure ulcers including bedsores and venous leg ulcers. It regenerates faster and aids healing of diabetic foot ulcers.

hEGF from LOKA

Is manufactured as Bulk hEGF API

Is manufactured at a capacity of up to 1 million Ointment tubes (Equivalent)

LiRaGlutide contains Liraglutide, an analog of human GLP-1 and acts as a GLP-1 receptor agonist. The peptide precursor of Liraglutide, produced by a process that includes expression of recombinant DNA in E.coli, has been engineered to be 97% homologous to native human GLP-1 by substituting arginine for lysine at position 34.

Liraglutide is made by attaching a C-16 fatty acid (palmitic acid) with a glutamic acid spacer on the remaining lysine residue at position 26 of the peptide precursor. The molecular formula of liraglutide is C172H265N43O51 and the molecular weight is 3751.2 Daltons. 

LiRaGlutide from LOKA

Is manufactured as Bulk Liraglutide API

Is manufactured at a capacity of 10 Kilograms ( Equivalent to 1 million Cartridges/PFS/Vials)